To describe baseline and emergent HIV-1 resistance to elvitegravir / cobicistat/emtricitabine/tenofovir DF ( EVG/COBI/FTC / TDF ) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF ( ATV+RTV+FTC / TDF ) in HIV-1-infected , treatment-nave subjects through 144 weeks .